期刊文献+

血液中炎症相关指标的动态变化及其与静脉血栓栓塞症的相关性 被引量:11

Dynamic changes of inflammation-related indices in venous thromboembolism and the associationbetween these indices and venous thromboembolism
原文传递
导出
摘要 目的探讨血液中炎症相关指标在静脉血栓栓塞症(VTE)病程中的动态变化及其与VTE的相关性。方法将2010年1至12月于北京朝阳医院呼吸与危重症医学科收治的95例VTE患者(男41例,女54例)的血液中白细胞计数(WBC)、中性粒细胞(NE)、纤维蛋白原(FBG)、C反应蛋白(CRP)、红细胞沉降率(ESR)等炎症相关指标与正常参考值范围进行比较,回顾性分析不同病程分期这些指标的动态变化,并根据性别、年龄、VTE类型、体质指数、吸烟状态、病变特点分别对患者进行分组分析,探讨这些指标与VTE的相关性。结果VTE患者血液中NE(0.72)、CRP(15.0mg/L)及男性患者ESR(20.0mm/1h)水平均高于正常参考值范围,而WBC(男7.27×10’/L、女8.67×10’/L)、FBG(男3621ms/L、女5201ms/L)及女性患者的ESR(19.5ram/1h)水平均在正常参考值范围。CRP在VTE急性期(平均秩次值49.72)和亚急性期(平均秩次值44.80)高于慢性期(平均秩次值30.25);年龄〉150岁者FBG、CRP、ESR高于年龄〈50岁者(平均秩次值分别为48.83比34.53,44.32比28.90,45.95比27.84);非肥胖者WBC水平高于肥胖者(平均秩次值为52.96比36.46);吸烟者FBG、CRP高于与非吸烟者(平均秩次值分别为57.75比42.69,53.92比37.75);累及外周肺动脉者FBG、GRP、ESR水平高于未累及外周肺动脉者(平均秩次值分别为59.24比37.39,52.68比33.19,50.08比36.55);上述差异均有统计学意义(均P〈0.05)。结论部分临床常用的炎症相关指标在ⅥE患者中升高,且在VrE急性期和亚急性期以及高龄、非肥胖、吸烟、累及外周肺动脉的VTE患者中较明显。 Objective To evaluate the dynamic changes of inflammation-related indices in blood during the development of venous thromhoembolism (VTE) and the association between these indices and VTE. Methods A total of 95 VTE hospitalized patients (41 males, 54 females ) were recruited from Department of Respiratory and Critical Care Medicine, Beijing Chaoyang Hospital from January 2010 toDecember 2010. Comparisons of inflammation-related indices including white blood cell (WBC), neutrophil ( NE), fibrinogen ( FBG), C-reactive protein (CRP) and erythrocyte sedimentation rate (ESR) were conducted between VTE patients and normal ranges. And the dynamic changes of these indices during the development of VTE were evaluated. Then they were divided into subgroups according to disease stage, gender, age, VTE type, body mass index, smoking status and clinical manifestations. And statistical analyses were performed to elucidate the associations between these indices and VTE. Results The levels of NE and CRP in VTE patients (0. 72, 15.0 mg/L) and ESR in male VTE patients (20. 0 mm/1 h) were elevated compared with normal ranges; while WBC ( male 7.27 x 109/L, female 8.67 x 109/L) , FBG (male 3621 mg/L, female 3201 mg/L) and female ESR (19. 5 ram/1 h) in VTE patients were within the normal ranges. The level of CRP was higher in acute ( mean rank order value : 49.72) and sub-acute ( mean rank order value: 44. 80) VTE patients than chronic VTE patients (mean rank order value: 30. 25 ). The level of FBG, CRP and ESR in patients t〉50 years old increased versus those 〈 50 years old (mean rank order values 48.83 vs 34. 53,44.32 vs 28.90 and 45.95 vs 27.84 respectively) , the patients whose body mass index (BMI) 〈25 kg/m2 had higher WBC level than those whose BMI I〉25 kg/m2(mean rank order values 52. 96 vs 36. 46) ; smoking VTE patients had elevated FBG and CRP levels than non-smoking VTE patients (mean rank order values 57. 75 vs 42. 69 and 53.92 vs 37. 75 respectively) ; compared with those without clinical manifestations of periphery pulmonary artery involved, the patients with clinical manifestations had higher levels of FBG, CRP and ESR ( mean rank order values 59. 24 vs 37. 39, 52. 68 vs 33.19 and 50. 08 vs 36. 55 respectively). The above differences had statistical significance ( all P 〈 0. 05 ). Conclusions Some inflammation-related indices frequently used in clinical settings become elevated in VTE patients. Part of these indices show higher levels in VTE acute and sub-acnte stages, and in older, nonobese, smoking and periphery pulmonary artery involved VTE patients.
出处 《中华医学杂志》 CAS CSCD 北大核心 2013年第24期1860-1863,共4页 National Medical Journal of China
基金 国家自然科学基金,国家973计划项目,国家"十二五"科技支撑计划,国家"十一五"科技支撑计划,北京科技新星计划,首都卫生发展科研专项
关键词 静脉血栓形成 白细胞 纤维蛋白原 C反应蛋白质 血沉 Venous thrombosis Leukocytes Fibrinogen C-reactive protein Bloodsedimentation
  • 相关文献

参考文献16

  • 1Kahn SR, Shrier I, Julian JA, et al. Determinants and time course of the post thrombotic syndrome after acute deep venous thrombosis. Ann Intern Med, 2008, 149: 698-707.
  • 2Condliffe R, Kiely DG, Gibbs JS, et al. Prognostic and aetiological factors in chronic thromboembolic pulmonary hvoertension. Eur ResDir J. 2009. 33 : 332-338.
  • 3翟振国,王军.慢性血栓栓塞性肺动脉高压的发病机制[J].中华医学杂志,2012,92(26):1807-1809. 被引量:15
  • 4van Aken BE, den Heijer M, Bos GM, et al. Recurrent venous thrombosis and markers of inflammation. Thromb Haemost, 2000, 83 : 536-539.
  • 5Zee RY, Glynn RJ, Cheng S, et al. An evaluation of candidate genes of inflammation and thrombosis in relation to the risk of venous thromboembolism: The Women's Genome Health Study. Circ Cardiovasc Genet, 2009, 2: 57-62.
  • 6Tsai AW, Cushman M, Rosamond WD, et al. Coagulation factors, inflammation markers, and venous thromboembolism : the longitudinal investigation of thromboembolism etiology ( LITE ) . Am J Med, 2002, 113: 636-642.
  • 7Connolly GC, Khorana AA, Kuderer NM, et al. Leukocytosis, thrombosis and early mortality in cancer patients initiating chemotherapy. Thromb Res, 2010, 126: 113-118.
  • 8Reitsma PH, Branger J, Van Den Blink B, et al. Procoagulant protein levels are differentially increased during human endotoxemia. J Thromb Haemost, 2003, 1: 1019-1023.
  • 9Fibrinogen Studies Collaboration, Danesh J, Lewington S, et al. Plasma fibrinogen level and the risk of major cardiovascular diseases and nonvascular mortality: an individual participant meta- analysis. JAMA, 2005, 294: 1799-1809.
  • 10Kamphuisen PW, Eikenboom JC, Vos HL, et al. Increased levels of factor V and fibrinogen in patients with venous thrombosis are not caused byacute phase reactions. Thromb Haemost, 1999, 81: 680-683.

二级参考文献14

  • 1Galie N, Kim NH. Pulmonary microvascular disease in chronic thromboembolic pulmonary hypertension. Proc Am Thorac Soc, 2006, 3: 571-576.
  • 2Muszbek L, Adany R, Mikkola H. Novel aspects of blood coagulation factor XIII. I. Structure, distribution, activation, and function. Crit Rev Clin Lab Sci, 1996, 33: 357-421.
  • 3Standeven KF, Grant PJ, Carter AM, et al. Functional analysis of the fibrinogen Aalpha Thr312Ala polymorphism: effects on fibrin structure and function. Circulation, 2003, 107 : 2326-2330.
  • 4Machado RD, Pauciulo MW, Thomson JR, et al. BMPR2 haploinsufficiency as the inherited molecular mechanism for primary pulmonary hypertension. Am J Hum Genet, 2001, 68: 92-102.
  • 5Suntharalingam J, Machado RD, Sharpies LD, et al. Demographic features, BMPR2 status and outcomes in distal chronic thromboembolic pulmonary hypertension. Thorax, 2007, 62 : 617-622.
  • 6Koehler R, Olschewski H, Hoeper M, et al. Serotonin transporter gene polymorphism in a cohort of German patients with idiopathic pulmonary arterial hypertension or chronic thromboembolic pulmonary hypertension. Chest, 2005, 128 : 619S.
  • 7Haoming S, Lemin W, Zhu G, et al. T Cell-mediated immune deficiency or compromise in patients with CTEPH. Am J Respir Crit Care Med, 2011, 183: 417-418.
  • 8Quarck R, Nawrot T, Meyns B, et al. C-reactive protein: a new predictor of adverse outcome in pulmonary arterial hypertension. J Am Coil Cardiol, 2009, 53: 1211-1218.
  • 9Soon E, Holmes AM, Barker L, et al. Inflammatory cytokines are elevated in patients with operable chronic thromboembolic pulmonary hypertension and predict outcome post-endarterectomy. Thorax, 2010, 65: A45.
  • 10Kimura H, Okada O, Tanabe N, et al. Plasma monocyte chemoattractant protein-1 and pulmonary vascular resistance in chronic thromboembolic pulmonary hypertension. Am J Respir Crit Care Med, 2001, 164: 319-324.

共引文献14

同被引文献72

  • 1陈桂金,万友利,李明,钱璞,徐建明.D-二聚体、超敏C反应蛋白联合Wells评分对早期静脉血栓栓塞症的诊断价值[J].血管与腔内血管外科杂志,2021,7(2):214-217. 被引量:7
  • 2王泽宇,吴允孚.C反应蛋白检测在治疗呼吸机相关性肺炎中的作用[J].实用老年医学,2013,27(1):38-40. 被引量:22
  • 3姜正华,吕元文,桑慧颖,朱慕云,朱湘平,丁平.慢性呼吸衰竭患者血栓前状态的研究[J].中华急诊医学杂志,2007,16(1):75-77. 被引量:15
  • 4马晓娟,殷惠军,陈可冀.血瘀证与炎症相关性的研究进展[J].中国中西医结合杂志,2007,27(7):669-672. 被引量:121
  • 5刘恒方,李新华,杨期东,苗旺,齐尚书,宋喜明,何庚山,董洪林,张福全.人颈动脉粥样硬化斑块环氧化物酶-2及I型前列腺素合成酶的表达[J].中华医学遗传学杂志,2007,24(4):453-456. 被引量:5
  • 6Surin WR,Prakash P,Barthwal MK,et al.Optimization of ferric chloride induced thrombosis model in rats:effect of anti-platelet and anticoagulant drugs[J] .J Pharmacol Toxicol Methods,2010,61 (3):287-291.
  • 7Cai XY,Lu L,Wang YN,et al.Association of increased S100B,S100A6 and S100P in serum levels with acute coronary syndrome and also with the severity of myocardial infarction in cardiac tissue of rat models with ischemia-reperfusion injury[J] .Atherosclerosis,2011,217 (2):536-542.
  • 8Healy AM,Pickard MD,Pradhan AD,et al.Platelet expression profiling and clinical validation of myeloid-related protein-14 as a novel determinant of cardiovascular events[J] .Circulation,2006,113 (19):2278-2284.
  • 9Morrow DA,Wang Y,Croce K,et al.Myeloid-related protein 8/14 and the risk of cardiovascular death or myocardial infarction after an acute coronary syndrome in the Pravastatin or Atorvastatin Evaluation and Infection Therapy:Thrombolysis in Myocardial Infarction (PROVE IT-TI-MI 22) trial[J] .Am Heart J,2008,155 (1):49-55.
  • 10Mjelva OR,Brügger-Andersen T,P(o)nitz V,et al.Long-term prognostic utility of PAPP-A and calprotectin in suspected acute coronary syndrome[J] .Scand Cardiovasc J,2013,47(2):88-97.

引证文献11

二级引证文献38

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部